Last reviewed · How we verify
control live attenuated mumps vaccine
control live attenuated mumps vaccine is a Biologic drug developed by Sinovac Research and Development Co., Ltd.. It is currently in Phase 3 development for Prevention of mumps.
The control live attenuated mumps vaccine works by introducing a weakened form of the mumps virus to stimulate an immune response.
The control live attenuated mumps vaccine works by introducing a weakened form of the mumps virus to stimulate an immune response. Used for Prevention of mumps.
At a glance
| Generic name | control live attenuated mumps vaccine |
|---|---|
| Sponsor | Sinovac Research and Development Co., Ltd. |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This immune response helps the body recognize and fight the mumps virus, providing protection against the disease. The vaccine is made from a weakened form of the virus, which cannot cause the disease but still triggers an immune response.
Approved indications
- Prevention of mumps
Common side effects
- Injection site pain
- Fatigue
- Headache
Key clinical trials
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months (PHASE3)
- Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis (PHASE3)
- Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants (PHASE2)
- Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants (PHASE3)
- Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines (PHASE4)
- Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- control live attenuated mumps vaccine CI brief — competitive landscape report
- control live attenuated mumps vaccine updates RSS · CI watch RSS
- Sinovac Research and Development Co., Ltd. portfolio CI
Frequently asked questions about control live attenuated mumps vaccine
What is control live attenuated mumps vaccine?
How does control live attenuated mumps vaccine work?
What is control live attenuated mumps vaccine used for?
Who makes control live attenuated mumps vaccine?
What development phase is control live attenuated mumps vaccine in?
What are the side effects of control live attenuated mumps vaccine?
Related
- Manufacturer: Sinovac Research and Development Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of mumps
- Compare: control live attenuated mumps vaccine vs similar drugs
- Pricing: control live attenuated mumps vaccine cost, discount & access